SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin inches up as USFDA grants mexiletine orphan drug designation

08 Jun 2020 Evaluate
Lupin is currently trading at Rs. 903.55, up by 1.25 points or 0.14% from its previous closing of Rs. 902.30 on the BSE.

The scrip opened at Rs. 906.00 and has touched a high and low of Rs. 911.15 and Rs. 881.00 respectively. So far 76640 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 923.55 on 05-Jun-2020 and a 52 week low of Rs. 505.00 on 13-Mar-2020.

Last one week high and low of the scrip stood at Rs. 923.55 and Rs. 845.60 respectively. The current market cap of the company is Rs. 40802.58 crore.

The promoters holding in the company stood at 46.92%, while Institutions and Non-Institutions held 39.23% and 13.85% respectively.

Lupin has received Orphan Drug Designation (ODD) from US Food and Drug Administration (USFDA) to mexiletine hydrochloride for the treatment of myotonic disorders. Myotonic disorders are a group of heterogeneous, inherited, neuromuscular disorders characterized by a shared symptom called myotonia. Myotonia is an inability to relax a contraction of skeletal muscle which originates from a voluntary muscular contraction such as shaking someone’s hand and blinking, or everyday activities such as walking across a street and climbing stairs. Mexiletine reduces myotonia symptoms, resulting in a significant improvement in patient quality-of-life and other functional outcomes.

The FDA grants ODD status to medicines intended for the treatment, diagnosis or prevention of rare diseases or disorders that affect fewer than 200,000 people in the US.

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India.


Lupin Share Price

2377.90 -81.85 (-3.33%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×